Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07671417 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Imaging Study in Metastatic Clear Cell RCC.

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 3 changed
See other at-risk trials from RayzeBio, Inc.

Record History

  1. Recruitment opened Trial sites expanded: 1 → 4 locations · Primary completion date: Dec 2026 to Jan 2027 · Completion date: Jan 2027 to Feb 2027 · 2 more Show 5 more changesShow less
    • Trial sites expanded: 1 → 4 locations
    • Primary completion date: Dec 2026 to Jan 2027
    • Completion date: Jan 2027 to Feb 2027
    • Start date changed from estimate of Jun 2026 to Jun 15, 2026
    • Eligibility criteria expanded, about 4 words
  2. Primary endpoint(s) modified Study title shortened, about 4 wordsv2 Show 1 more changeShow less
    • Study title shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).
Trial Details
NCT Number NCT07671417
Lead Sponsor RayzeBio, Inc.
Conditions Metastatic Clear Cell Renal Cell Carcinoma
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov